Retrospective analyses
| No. overall . | No. with SR-aGVHD . | CR, n (%) . | ORR, % . | Comment . | Reference . |
|---|---|---|---|---|---|
| 95 | 54 | 25 (46.3) | 81.5 | Multicenter United States and European Union; previous lines 3 (1-7) | 11 |
| 43 | 19 | 12 (63) | 84 | 25 | |
| 23 | 23 | 5 (22) | 69.5 | Multicenter Spain Grupo Español de Trasplante Hematopoyético; previous lines 3 | 26 |
| 75 | 32 | 20 (63) | 75 | Single center: adults and children; median follow-up, 28 mo | 27 |
| 22 | 13 | 4 (31) | 77 | Pediatrics | 28 |
| 13 | 11 | 4 (36) | 45 | Pediatrics | 29 |
| 29 | 13 | 9 (69) | 84 | Pediatrics | 30 |
| No. overall . | No. with SR-aGVHD . | CR, n (%) . | ORR, % . | Comment . | Reference . |
|---|---|---|---|---|---|
| 95 | 54 | 25 (46.3) | 81.5 | Multicenter United States and European Union; previous lines 3 (1-7) | 11 |
| 43 | 19 | 12 (63) | 84 | 25 | |
| 23 | 23 | 5 (22) | 69.5 | Multicenter Spain Grupo Español de Trasplante Hematopoyético; previous lines 3 | 26 |
| 75 | 32 | 20 (63) | 75 | Single center: adults and children; median follow-up, 28 mo | 27 |
| 22 | 13 | 4 (31) | 77 | Pediatrics | 28 |
| 13 | 11 | 4 (36) | 45 | Pediatrics | 29 |
| 29 | 13 | 9 (69) | 84 | Pediatrics | 30 |
CR, complete remission; ORR, overall response rate.